SEC Filing Summary: GSK Plc (Form 13F-HR)
Business Context and Reporting Period
This filing is a Form 13F-HR submitted by GSK Plc, an institutional investment manager based in London, United Kingdom. The report covers the calendar quarter ended March 31, 2026, and was signed by Victoria Whyte on May 9, 2026. The filing discloses the equity securities held by the manager at the end of the reporting period.
Key Financial Metrics
As a Form 13F filing, this document reports portfolio holdings rather than the operating financial performance of GSK Plc itself. The following metrics relate to the reported investment portfolio:
- Total Portfolio Value: $599,153,380 (rounded to the nearest dollar).
- Number of Holdings: 13 distinct entries reported in the Information Table.
- Other Included Managers: 0 (No other managers are included in this report).
Note: This filing does not provide data on GSK Plc's revenue, profit, cash flow, margins, debt, or liquidity. Those metrics are found in the company's 10-K or 20-F filings.
Material Changes
The provided text contains only the cover page and summary data for the current quarter. It does not include the detailed schedule of holdings or comparative data from the prior period (December 31, 2025). Therefore, material changes in specific positions or total portfolio value versus the prior period cannot be determined from this text.
Guidance, Outlook, and Risks
This filing type does not contain management commentary, forward-looking guidance, risk factors, or contingencies regarding the company's business operations. It is a regulatory disclosure of investment positions.
Key Facts for Investor Verification
- Verify the specific 13 holdings listed in the full Information Table (not included in the provided text) to understand the manager's current asset allocation.
- Confirm the total value of $599,153,380 against the sum of individual holdings in the full report.
- Note that this report reflects positions as of March 31, 2026, and does not reflect subsequent trading activity.
- Recognize that this document does not disclose GSK Plc's own financial health or operational results.